Matches in DBpedia 2015-10 for { <http://dbpedia.org/resource/Oritavancin> ?p ?o }
- Oritavancin abstract "Oritavancin (INN, also known as LY333328, Orbactiv) is a novel semisynthetic glycopeptide antibiotic being developed for the treatment of serious Gram-positive bacterial infections. Originally discovered and developed by Eli Lilly, oritavancin was acquired by InterMune in 2001 and then by Targanta Therapeutics in late 2005.In December 2008, the US Food and Drug Administration declined to approve it without additional studies, and an EU application was withdrawn. In 2009, the development rights were acquired by The Medicines Company, which has completed clinical trials and submitted a new drug application to the FDA in February 2014. On August 6, 2014, the FDA approved oritavancin for treatment of skin infections in the United States. Its chemical structure is similar to vancomycin. It is a lipoglycopeptide.".
- Oritavancin atcPrefix "J01".
- Oritavancin atcSuffix "XA05".
- Oritavancin casNumber "171099-57-3".
- Oritavancin chEBI "82699".
- Oritavancin fdaUniiCode "PUG62FRZ2E".
- Oritavancin iupacName "(4R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-α-(L)-arabinohexopyranosyl)-N3-(p-(p-chlorophenyl)benzyl)vancomycin".
- Oritavancin pubchem "16131319".
- Oritavancin thumbnail Oritavancin.svg?width=300.
- Oritavancin wikiPageExternalLink single-dose-of-antibiotic-found-effective-in-quelling-mrsa.html.
- Oritavancin wikiPageID "10285600".
- Oritavancin wikiPageLength "12244".
- Oritavancin wikiPageOutDegree "24".
- Oritavancin wikiPageRevisionID "678992871".
- Oritavancin wikiPageWikiLink Acute_bacterial_skin_and_skin-structure_infection.
- Oritavancin wikiPageWikiLink Anthrax.
- Oritavancin wikiPageWikiLink Bacillus_anthracis.
- Oritavancin wikiPageWikiLink Biphenyl.
- Oritavancin wikiPageWikiLink Category:Eli_Lilly_and_Company.
- Oritavancin wikiPageWikiLink Category:Glycopeptide_antibiotics.
- Oritavancin wikiPageWikiLink Cefalexin.
- Oritavancin wikiPageWikiLink Cephalexin.
- Oritavancin wikiPageWikiLink Clostridium_difficile.
- Oritavancin wikiPageWikiLink Clostridium_difficile_colitis.
- Oritavancin wikiPageWikiLink Eli_Lilly_and_Company.
- Oritavancin wikiPageWikiLink Enterococci.
- Oritavancin wikiPageWikiLink Enterococcus.
- Oritavancin wikiPageWikiLink Food_and_Drug_Administration.
- Oritavancin wikiPageWikiLink Glycopeptide_antibiotic.
- Oritavancin wikiPageWikiLink Gram-positive_bacterial_infection.
- Oritavancin wikiPageWikiLink International_Nonproprietary_Name.
- Oritavancin wikiPageWikiLink Lipoglycopeptide.
- Oritavancin wikiPageWikiLink Methicillin-resistant_Staphylococcus_aureus.
- Oritavancin wikiPageWikiLink New_drug_application.
- Oritavancin wikiPageWikiLink New_drug_application_(FDA).
- Oritavancin wikiPageWikiLink Pathogenic_bacteria.
- Oritavancin wikiPageWikiLink Semisynthesis.
- Oritavancin wikiPageWikiLink Semisynthetic.
- Oritavancin wikiPageWikiLink Skin_and_skin_structure_infection.
- Oritavancin wikiPageWikiLink Skin_infections.
- Oritavancin wikiPageWikiLink Staphylococcus_aureus.
- Oritavancin wikiPageWikiLink Streptococci.
- Oritavancin wikiPageWikiLink Streptococcus.
- Oritavancin wikiPageWikiLink Targanta_Therapeutics_Corporation.
- Oritavancin wikiPageWikiLink The_New_York_Times.
- Oritavancin wikiPageWikiLink US_Food_and_Drug_Administration.
- Oritavancin wikiPageWikiLink Vancomycin.
- Oritavancin wikiPageWikiLinkText "Oritavancin".
- Oritavancin wikiPageWikiLinkText "oritavancin".
- Oritavancin atcPrefix "J01".
- Oritavancin atcSuffix "XA05".
- Oritavancin c "86".
- Oritavancin casNumber "171099".
- Oritavancin chebi "82699".
- Oritavancin chemspiderid "31149229".
- Oritavancin cl "3".
- Oritavancin h "97".
- Oritavancin hasPhotoCollection Oritavancin.
- Oritavancin inchi "1".
- Oritavancin inchikey "VHFGEBVPHAGQPI-MYYQHNLBBW".
- Oritavancin iupacName "-22".
- Oritavancin molecularWeight "1793.1".
- Oritavancin n "10".
- Oritavancin o "26".
- Oritavancin pubchem "16131319".
- Oritavancin routesOfAdministration "Intravenous".
- Oritavancin smiles "C[C@H]1[C@@H]O".
- Oritavancin stdinchi "1".
- Oritavancin stdinchikey "VHFGEBVPHAGQPI-MYYQHNLBSA-N".
- Oritavancin tradename "Orbactiv".
- Oritavancin unii "PUG62FRZ2E".
- Oritavancin verifiedfields "changed".
- Oritavancin verifiedrevid "447756219".
- Oritavancin watchedfields "changed".
- Oritavancin wikiPageUsesTemplate Template:Cell_wall_disruptive_antibiotics.
- Oritavancin wikiPageUsesTemplate Template:Cite_news.
- Oritavancin wikiPageUsesTemplate Template:Drugbox.
- Oritavancin wikiPageUsesTemplate Template:Reflist.
- Oritavancin subject Category:Eli_Lilly_and_Company.
- Oritavancin subject Category:Glycopeptide_antibiotics.
- Oritavancin hypernym Being.
- Oritavancin type Article.
- Oritavancin type Biomolecule.
- Oritavancin type ChemicalSubstance.
- Oritavancin type Company.
- Oritavancin type Drug.
- Oritavancin type Article.
- Oritavancin type Biomolecule.
- Oritavancin type Chemical.
- Oritavancin type Company.
- Oritavancin type ChemicalObject.
- Oritavancin type Thing.
- Oritavancin type Q8386.
- Oritavancin comment "Oritavancin (INN, also known as LY333328, Orbactiv) is a novel semisynthetic glycopeptide antibiotic being developed for the treatment of serious Gram-positive bacterial infections. Originally discovered and developed by Eli Lilly, oritavancin was acquired by InterMune in 2001 and then by Targanta Therapeutics in late 2005.In December 2008, the US Food and Drug Administration declined to approve it without additional studies, and an EU application was withdrawn.".
- Oritavancin label "Oritavancin".
- Oritavancin sameAs أوريتافانسين.
- Oritavancin sameAs Oritavancine.
- Oritavancin sameAs m.02q7dw8.
- Oritavancin sameAs Оритаванцин.
- Oritavancin sameAs Oritavancin.